Translating Genetic Insights Into Treatments for Alzheimer’s Disease

October 15, 2020, 4:00 pm — 4:45 pm

Due to the COVID-19 outbreak, Precision Medicine Thursdays at Venture Café have moved to Zoom.

Zoom Meeting Registration: https://zoom.us/meeting/register/tJ0pdeGqqD4jG9NC1S7eHut2l_T4vuldTHbF

The Institute of Clinical and Translational Sciences (ICTS), in collaboration with Venture Café, is hosting Precision Medicine Series on the third Thursday of every month! This month at ICTS Precision Medicine Thursday, join us to hear two researchers from Washington University School of Medicine in St. Louis, Marco Colonna, MD, Professor of Immunobiology and David Holtzman, MD, Andrew B & Gretchen P Jones Professor of Neurology.

This month at Precision Medicine Thursday at Venture Café, Drs. Marco Colonna and David Holtzman will discuss genetic risk factors for Alzheimer’s disease and the development of potential therapeutics that target these genes. Dr. Colonna will speak about the role of the TREM2 gene in the development of early onset dementia and Alzheimer’s disease and testing of cytokine IL-34 as a therapeutic target for neurodegenerative diseases while Dr. Holtzman will discuss the Apolipoprotein E (ApoE) gene which is the strongest genetic risk factor for Alzheimer’s disease. He will discuss how ApoE4 strongly increases Alzheimer’s disease risk while ApoE2 decreases risk and has the potential to slow down the progression of cognitive decline due to Alzheimer’s disease.

For more information, please contact Tricia Salyer, Precision Medicine Navigator at ICTS, at salyerp@wustl.edu.